• 92% serous• BRCA1/2-mutated high-grade ovarian carcinoma• ≥2 prior lines of chemotherapy• ≥3 prior lines of chemotherapy• Platinum-resistant (19%)• Platinum-sensitive (75%). This evidence concerns the gene BRCA1 and ovarian carcinoma.